Cargando…
UHPLC-HRMS data from non-targeted screening for biotransformation products of cytostatic drug imatinib
Imatinib is a selective tyrosine kinase inhibitor used to treat chronic myeloid leukemia. It enters the environment by excretion from the body through urine and feces and is transferred with wastewater to a wastewater treatment plant. There, it can be degraded by activated sludge, forming a number o...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897666/ https://www.ncbi.nlm.nih.gov/pubmed/35257019 http://dx.doi.org/10.1016/j.dib.2022.107991 |
_version_ | 1784663472260251648 |
---|---|
author | Tkalec, Žiga Negreira, Noelia López de Alda, Miren Barceló, Damiá Kosjek, Tina |
author_facet | Tkalec, Žiga Negreira, Noelia López de Alda, Miren Barceló, Damiá Kosjek, Tina |
author_sort | Tkalec, Žiga |
collection | PubMed |
description | Imatinib is a selective tyrosine kinase inhibitor used to treat chronic myeloid leukemia. It enters the environment by excretion from the body through urine and feces and is transferred with wastewater to a wastewater treatment plant. There, it can be degraded by activated sludge, forming a number of biotransformation products. Presence of imatinib and its potential transformation products in the environment can impose a high risk to aquatic organisms and human health, therefore it is important to obtain knowledge of its environmental fate. The data presented here is a result of a simulated biodegradation of imatinib at two levels of activated sludge using a batch biotransformation setup, with and without carbon source. The data was acquired with UHPLC-HRMS/MS and processed by MzMine2.36 [1]. The dataset presents a table of [M+H](+) features with retention times and corresponding MS/MS data. With development of new data mining tools this data can be used to identify new transformation products of imatinib and with it fully understand its environmental fate and the risk associated with its presence in the environment. |
format | Online Article Text |
id | pubmed-8897666 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-88976662022-03-06 UHPLC-HRMS data from non-targeted screening for biotransformation products of cytostatic drug imatinib Tkalec, Žiga Negreira, Noelia López de Alda, Miren Barceló, Damiá Kosjek, Tina Data Brief Data Article Imatinib is a selective tyrosine kinase inhibitor used to treat chronic myeloid leukemia. It enters the environment by excretion from the body through urine and feces and is transferred with wastewater to a wastewater treatment plant. There, it can be degraded by activated sludge, forming a number of biotransformation products. Presence of imatinib and its potential transformation products in the environment can impose a high risk to aquatic organisms and human health, therefore it is important to obtain knowledge of its environmental fate. The data presented here is a result of a simulated biodegradation of imatinib at two levels of activated sludge using a batch biotransformation setup, with and without carbon source. The data was acquired with UHPLC-HRMS/MS and processed by MzMine2.36 [1]. The dataset presents a table of [M+H](+) features with retention times and corresponding MS/MS data. With development of new data mining tools this data can be used to identify new transformation products of imatinib and with it fully understand its environmental fate and the risk associated with its presence in the environment. Elsevier 2022-02-23 /pmc/articles/PMC8897666/ /pubmed/35257019 http://dx.doi.org/10.1016/j.dib.2022.107991 Text en © 2022 The Author(s). Published by Elsevier Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Data Article Tkalec, Žiga Negreira, Noelia López de Alda, Miren Barceló, Damiá Kosjek, Tina UHPLC-HRMS data from non-targeted screening for biotransformation products of cytostatic drug imatinib |
title | UHPLC-HRMS data from non-targeted screening for biotransformation products of cytostatic drug imatinib |
title_full | UHPLC-HRMS data from non-targeted screening for biotransformation products of cytostatic drug imatinib |
title_fullStr | UHPLC-HRMS data from non-targeted screening for biotransformation products of cytostatic drug imatinib |
title_full_unstemmed | UHPLC-HRMS data from non-targeted screening for biotransformation products of cytostatic drug imatinib |
title_short | UHPLC-HRMS data from non-targeted screening for biotransformation products of cytostatic drug imatinib |
title_sort | uhplc-hrms data from non-targeted screening for biotransformation products of cytostatic drug imatinib |
topic | Data Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897666/ https://www.ncbi.nlm.nih.gov/pubmed/35257019 http://dx.doi.org/10.1016/j.dib.2022.107991 |
work_keys_str_mv | AT tkalecziga uhplchrmsdatafromnontargetedscreeningforbiotransformationproductsofcytostaticdrugimatinib AT negreiranoelia uhplchrmsdatafromnontargetedscreeningforbiotransformationproductsofcytostaticdrugimatinib AT lopezdealdamiren uhplchrmsdatafromnontargetedscreeningforbiotransformationproductsofcytostaticdrugimatinib AT barcelodamia uhplchrmsdatafromnontargetedscreeningforbiotransformationproductsofcytostaticdrugimatinib AT kosjektina uhplchrmsdatafromnontargetedscreeningforbiotransformationproductsofcytostaticdrugimatinib |